Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-endoglin siRNA
- Development stage
- Preclinical
- Lead developer
- University of Alabama at Birmingham
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal
01
Overview
Anti-endoglin siRNA is a small interfering RNA (siRNA) designed to silence the expression of endoglin (ENG, CD105), a type I transmembrane glycoprotein and co-receptor for the TGF-beta superfamily. Endoglin is highly expressed on the surface of proliferating vascular endothelial cells and certain chemoresistant tumor cells, making it a dual target for anti-angiogenic and cell-specific therapy. By reducing endoglin levels, this siRNA induces double-stranded DNA damage and suppresses the expression of key DNA repair genes, including BARD1 and BRCA1, thereby enhancing the efficacy of platinum-based chemotherapies like carboplatin and cisplatin. In preclinical research, it has been formulated using chitosan-encapsulated nanoparticles for systemic delivery in orthotopic ovarian cancer models.
- Other names
- anti-endoglin small interfering RNAendoglin siRNA
02
Targets
TLR3 (Toll-like receptor 3)IFIH1 (MDA5)Endoglin mRNA (ENG mRNA)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)
Beyond the preview
Go deeper on anti-endoglin siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-endoglin siRNA.